Track market-moving stories before they get noisy

California State Teachers Retirement System boosted its stake in shares of Elevance Health, Inc. (NYSE:ELV – Free Report) by 37,390.0% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 124,019,670 shares of the company’s stock after buying an additional 123,688,863 shares during the quarter. California State Teachers Retirement System owned approximately 57.19% of Elevance Health worth $47,962,127,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in ELV. Kilter Group LLC purchased a new position in Elevance Health in the second quarter valued at about $28,000. Kemnay Advisory Services Inc. bought a new position in shares of Elevance Health during the 4th quarter valued at approximately $31,000. J.Safra Asset Management Corp purchased a new stake in shares of Elevance Health during the 4th quarter worth approximately $32,000. WealthCollab LLC raised its holdings in shares of Elevance Health by 42.2% in the 1st quarter. WealthCollab LLC now owns 91 shares of the company’s stock worth $27,000 after purchasing an additional 27 shares during the period. Finally, Elevation Wealth Partners LLC raised its holdings in shares of Elevance Health by 600.0% in the 2nd quarter. Elevation Wealth Partners LLC now owns 105 shares of the company’s stock worth $41,000 after purchasing an additional 90 shares during the period. Hedge funds and other institutional investors own 89.24% of the company’s stock.

Insider Buying and Selling In other Elevance Health news, Director Robert Dixon, Jr. sold 151 shares of the firm’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $401.77, for a total value of $60,667.27. Following the completion of the transaction, the director directly owned 10,734 shares of the company’s stock, valued at $4,312,599.18. This trade represents a 1.39% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.34% of the stock is currently owned by insiders.

Elevance Health Stock Performance NYSE:ELV opened at $407.05 on Monday. The business’s fifty day moving average is $396.72 and its 200 day moving average is $364.70. The firm has a market cap of $88.28 billion, a price-to-earnings ratio of 18.09, a PEG ratio of 2.12 and a beta of 0.69. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.52 and a current ratio of 1.52. Elevance Health, Inc. has a 52-week low of $274.84 and a 52-week high of $436.24. Elevance Health (NYSE:ELV – Get Free Report) last posted its earnings results on Wednesday, July 15th. The company reported $7.45 earnings per share for the quarter, beating analysts’ consensus estimates of $6.21 by $1.24. Elevance Health had a return on equity of 14.64% and a net margin of 2.47%.The business had revenue of $49.83 billion during the quarter, compared to analyst estimates of $48.88 billion. During the same quarter in the previous year, the firm earned $8.84 EPS. The company’s quarterly revenue was up .8% compared to the same quarter last year. Research analysts predict that Elevance Health, Inc. will post 27.18 EPS for the current year.

Elevance Health Announces Dividend The company also recently announced a quarterly dividend, which will be paid on Friday, September 25th. Shareholders of record on Thursday, September 10th will be paid a $1.72 dividend. The ex-dividend date is Thursday, September 10th. This represents a $6.88 annualized dividend and a yield of 1.7%. Elevance Health’s dividend payout ratio is currently 30.58%.

Analysts Set New Price Targets Several brokerages have weighed in on ELV. Deutsche Bank Aktiengesellschaft raised Elevance Health from a “hold” rating to a “buy” rating and increased their price objective for the company from $363.00 to $498.00 in a report on Wednesday, May 20th. UBS Group boosted their target price on Elevance Health from $400.00 to $460.00 and gave the company a “buy” rating in a research note on Friday, May 22nd. Evercore reaffirmed a “hold” rating on shares of Elevance Health in a research report on Tuesday, May 19th. Truist Financial increased their price target on Elevance Health from $450.00 to $475.00 and gave the stock a “buy” rating in a research note on Tuesday, July 14th. Finally, Robert W. Baird lifted their price objective on Elevance Health from $331.00 to $393.00 and gave the stock a “neutral” rating in a report on Thursday, July 16th. Fifteen research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $440.90.

Read Our Latest Research Report on ELV

Elevance Health Company Profile (Free Report)

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.

Featured Articles Five stocks we like better than Elevance Health AI Token Costs Are Changing the Hardware vs. Software Debate 3 ETFs That Could Move as Rate Expectations Shift 3 Stocks With September Catalysts Investors Shouldn’t Ignore Ollie’s Bargain Outlet Stock Falls on Weak Comps Despite Margin Gains

Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.

Beaconlight Capital LLC bought a new position in shares of Elevance Health, Inc. (NYSE:ELV – Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund bought 5,946 shares of the company’s stock, valued at approximately $2,299,000. Elevance Health makes up about 0.8% of Beaconlight Capital LLC’s investment portfolio, making the stock its 27th biggest position.

Other large investors also recently bought and sold shares of the company. BTG Pactual Asset Management US LLC acquired a new stake in Elevance Health in the 2nd quarter valued at about $350,000. Quantitative Investment Management LLC increased its stake in shares of Elevance Health by 90.6% during the second quarter. Quantitative Investment Management LLC now owns 2,184 shares of the company’s stock worth $844,000 after buying an additional 1,038 shares during the period. Sigma Planning Corp raised its holdings in Elevance Health by 43.3% in the second quarter. Sigma Planning Corp now owns 2,225 shares of the company’s stock valued at $861,000 after acquiring an additional 672 shares in the last quarter. Two Sigma Securities LLC lifted its stake in Elevance Health by 104.5% in the second quarter. Two Sigma Securities LLC now owns 2,796 shares of the company’s stock worth $1,081,000 after acquiring an additional 1,429 shares during the last quarter. Finally, Benjamin Edwards Inc. lifted its stake in Elevance Health by 9.4% in the second quarter. Benjamin Edwards Inc. now owns 4,105 shares of the company’s stock worth $1,587,000 after acquiring an additional 352 shares during the last quarter. Hedge funds and other institutional investors own 89.24% of the company’s stock.

Analysts Set New Price Targets A number of equities research analysts have commented on ELV shares. Evercore reissued a “hold” rating on shares of Elevance Health in a research report on Tuesday, May 19th. JPMorgan Chase & Co. lifted their price objective on shares of Elevance Health from $411.00 to $476.00 and gave the stock an “overweight” rating in a research report on Monday, June 8th. Wall Street Zen downgraded shares of Elevance Health from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Truist Financial increased their target price on Elevance Health from $450.00 to $475.00 and gave the company a “buy” rating in a report on Tuesday, July 14th. Finally, UBS Group lifted their price target on Elevance Health from $400.00 to $460.00 and gave the stock a “buy” rating in a report on Friday, May 22nd. Fifteen analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $440.90.

View Our Latest Report on Elevance Health Insider Transactions at Elevance Health In other Elevance Health news, Director Robert L. Dixon, Jr. sold 151 shares of Elevance Health stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $401.77, for a total value of $60,667.27. Following the transaction, the director directly owned 10,734 shares in the company, valued at approximately $4,312,599.18. The trade was a 1.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.34% of the company’s stock.

Elevance Health Price Performance Shares of ELV opened at $395.28 on Monday. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.52 and a quick ratio of 1.52. Elevance Health, Inc. has a 1-year low of $274.84 and a 1-year high of $436.24. The stock has a market cap of $85.72 billion, a PE ratio of 17.57, a price-to-earnings-growth ratio of 2.26 and a beta of 0.68. The firm has a fifty day moving average price of $395.36 and a 200 day moving average price of $362.31.

Elevance Health (NYSE:ELV – Get Free Report) last posted its earnings results on Wednesday, July 15th. The company reported $7.45 EPS for the quarter, topping analysts’ consensus estimates of $6.21 by $1.24. Elevance Health had a return on equity of 14.64% and a net margin of 2.47%.The business had revenue of $49.83 billion for the quarter, compared to analysts’ expectations of $48.88 billion. During the same quarter in the previous year, the firm earned $8.84 earnings per share. The business’s revenue was up .8% compared to the same quarter last year. As a group, sell-side analysts anticipate that Elevance Health, Inc. will post 27.18 EPS for the current year.

Elevance Health Announces Dividend The firm also recently declared a quarterly dividend, which will be paid on Friday, September 25th. Investors of record on Thursday, September 10th will be paid a dividend of $1.72 per share. The ex-dividend date is Thursday, September 10th. This represents a $6.88 dividend on an annualized basis and a yield of 1.7%. Elevance Health’s dividend payout ratio is currently 30.58%.

(Free Report)

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.

Further Reading Five stocks we like better than Elevance Health Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally Rubrik’s AI Security Bet Could Power the Next Leg Higher Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against? Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV – Free Report).

Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.

Barrow Hanley Mewhinney & Strauss LLC purchased a new stake in shares of Elevance Health, Inc. (NYSE:ELV – Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 452,636 shares of the company’s stock, valued at approximately $175,048,000. Barrow Hanley Mewhinney & Strauss LLC owned approximately 0.21% of Elevance Health at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. BlackRock Inc. purchased a new stake in Elevance Health in the second quarter worth $7,344,424,000. Bank of New York Mellon Corp purchased a new position in shares of Elevance Health during the 2nd quarter valued at $1,246,349,000. Norges Bank bought a new position in shares of Elevance Health during the 4th quarter worth $1,058,165,000. Wellington Management Group LLP grew its stake in shares of Elevance Health by 25.2% during the 4th quarter. Wellington Management Group LLP now owns 8,289,976 shares of the company’s stock worth $2,906,051,000 after acquiring an additional 1,668,679 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its holdings in Elevance Health by 27.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,446,185 shares of the company’s stock worth $2,610,261,000 after acquiring an additional 1,607,274 shares during the last quarter. Hedge funds and other institutional investors own 89.24% of the company’s stock.

Elevance Health Stock Performance Shares of ELV opened at $400.66 on Monday. Elevance Health, Inc. has a 52-week low of $274.84 and a 52-week high of $436.24. The stock’s 50-day simple moving average is $394.76 and its 200 day simple moving average is $360.04. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.52 and a current ratio of 1.52. The stock has a market capitalization of $86.89 billion, a price-to-earnings ratio of 17.81, a price-to-earnings-growth ratio of 2.29 and a beta of 0.68.

Elevance Health (NYSE:ELV – Get Free Report) last posted its earnings results on Wednesday, July 15th. The company reported $7.45 earnings per share for the quarter, beating analysts’ consensus estimates of $6.21 by $1.24. Elevance Health had a return on equity of 14.64% and a net margin of 2.47%.The business had revenue of $49.83 billion during the quarter, compared to analyst estimates of $48.88 billion. During the same quarter in the previous year, the firm earned $8.84 EPS. The company’s quarterly revenue was up .8% compared to the same quarter last year. Research analysts forecast that Elevance Health, Inc. will post 27.18 EPS for the current fiscal year. Elevance Health Announces Dividend The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 25th. Investors of record on Thursday, September 10th will be paid a dividend of $1.72 per share. The ex-dividend date of this dividend is Thursday, September 10th. This represents a $6.88 annualized dividend and a yield of 1.7%. Elevance Health’s payout ratio is currently 30.58%.

Insiders Place Their Bets In other Elevance Health news, Director Robert L. Dixon, Jr. sold 151 shares of the stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $401.77, for a total value of $60,667.27. Following the sale, the director directly owned 10,734 shares in the company, valued at $4,312,599.18. This represents a 1.39% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 0.34% of the company’s stock.

Analysts Set New Price Targets Several equities research analysts have commented on the stock. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $395.00 price objective on shares of Elevance Health in a report on Thursday, July 16th. Bank of America lifted their target price on shares of Elevance Health from $435.00 to $460.00 and gave the stock a “buy” rating in a research note on Thursday, June 4th. Barclays lowered their price target on shares of Elevance Health from $480.00 to $457.00 and set an “overweight” rating on the stock in a research report on Thursday, July 16th. Mizuho upped their price target on shares of Elevance Health from $435.00 to $465.00 and gave the company an “outperform” rating in a research note on Monday, June 8th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Elevance Health from $411.00 to $476.00 and gave the stock an “overweight” rating in a report on Monday, June 8th. Fifteen equities research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat, Elevance Health currently has a consensus rating of “Moderate Buy” and an average price target of $440.90.

Read Our Latest Stock Report on Elevance Health

(Free Report)

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.

Further Reading Five stocks we like better than Elevance Health VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You? 3 Closed-End Funds to Maximize Dividend Payments Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy? $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV – Free Report).

Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.

Asahi Life Asset Management CO. LTD. purchased a new stake in Elevance Health, Inc. (NYSE:ELV – Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 1,279 shares of the company’s stock, valued at approximately $495,000.

Several other large investors have also recently modified their holdings of the business. Sei Investments Co. boosted its holdings in Elevance Health by 7.7% in the second quarter. Sei Investments Co. now owns 163,668 shares of the company’s stock valued at $63,666,000 after acquiring an additional 11,745 shares during the last quarter. Glenview Trust co increased its position in shares of Elevance Health by 41.5% during the second quarter. Glenview Trust co now owns 1,619 shares of the company’s stock worth $630,000 after buying an additional 475 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its stake in Elevance Health by 6.9% during the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 65,945 shares of the company’s stock worth $25,650,000 after buying an additional 4,272 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Elevance Health by 5.0% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 42,371 shares of the company’s stock valued at $16,478,000 after acquiring an additional 2,012 shares during the last quarter. Finally, Quantinno Capital Management LP grew its holdings in Elevance Health by 111.8% during the 2nd quarter. Quantinno Capital Management LP now owns 43,911 shares of the company’s stock worth $17,080,000 after acquiring an additional 23,180 shares during the period. Institutional investors own 89.24% of the company’s stock.

Elevance Health Price Performance ELV stock opened at $398.53 on Thursday. The firm has a market capitalization of $86.43 billion, a P/E ratio of 17.71, a price-to-earnings-growth ratio of 2.29 and a beta of 0.68. Elevance Health, Inc. has a 12 month low of $274.84 and a 12 month high of $436.24. The firm has a 50 day moving average of $394.87 and a 200-day moving average of $359.27. The company has a current ratio of 1.52, a quick ratio of 1.52 and a debt-to-equity ratio of 0.68.

Elevance Health (NYSE:ELV – Get Free Report) last posted its quarterly earnings data on Wednesday, July 15th. The company reported $7.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.21 by $1.24. Elevance Health had a return on equity of 14.64% and a net margin of 2.47%.The company had revenue of $49.83 billion during the quarter, compared to analyst estimates of $48.88 billion. During the same quarter last year, the company earned $8.84 earnings per share. The firm’s quarterly revenue was up .8% on a year-over-year basis. As a group, sell-side analysts predict that Elevance Health, Inc. will post 27.07 earnings per share for the current fiscal year. Elevance Health Announces Dividend The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 25th. Stockholders of record on Thursday, September 10th will be given a dividend of $1.72 per share. The ex-dividend date is Thursday, September 10th. This represents a $6.88 annualized dividend and a dividend yield of 1.7%. Elevance Health’s dividend payout ratio is 30.58%.

Analyst Ratings Changes A number of research analysts have recently issued reports on the company. Barclays dropped their price objective on Elevance Health from $480.00 to $457.00 and set an “overweight” rating on the stock in a research note on Thursday, July 16th. UBS Group upped their price target on Elevance Health from $400.00 to $460.00 and gave the stock a “buy” rating in a research note on Friday, May 22nd. JPMorgan Chase & Co. increased their price target on Elevance Health from $411.00 to $476.00 and gave the stock an “overweight” rating in a report on Monday, June 8th. Truist Financial boosted their target price on shares of Elevance Health from $450.00 to $475.00 and gave the stock a “buy” rating in a research report on Tuesday, July 14th. Finally, Bank of America upped their price objective on shares of Elevance Health from $435.00 to $460.00 and gave the stock a “buy” rating in a research report on Thursday, June 4th. Fifteen analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat, Elevance Health has an average rating of “Moderate Buy” and a consensus target price of $440.90.

Check Out Our Latest Analysis on ELV

Insiders Place Their Bets In other Elevance Health news, Director Robert L. Dixon, Jr. sold 151 shares of the business’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $401.77, for a total value of $60,667.27. Following the completion of the sale, the director directly owned 10,734 shares of the company’s stock, valued at $4,312,599.18. The trade was a 1.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.34% of the stock is owned by corporate insiders.

(Free Report)

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.

Read More Five stocks we like better than Elevance Health Bloom Energy’s AI Surge Meets a Valuation Reality Check Target Is Winning Shoppers Back—Can the Rally Reach $180? IonQ’s Space Contract Points to a New Frontier for Quantum Investors Is Apple’s AI Strategy Smarter Than Skeptics Think?

Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.

Barden Capital Management Inc. acquired a new position in Elevance Health, Inc. (NYSE: ELV) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 1,609 shares of the company's stock, valued at approximately $622,000. A number of other institutional investors

Posted by Defense World Staff on Aug 13th, 2026

Ballast Inc. acquired a new stake in Elevance Health, Inc. (NYSE:ELV – Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 1,572 shares of the company’s stock, valued at approximately $608,000.

A number of other institutional investors and hedge funds have also made changes to their positions in ELV. WealthCollab LLC grew its holdings in Elevance Health by 42.2% during the 1st quarter. WealthCollab LLC now owns 91 shares of the company’s stock worth $27,000 after acquiring an additional 27 shares in the last quarter. Kemnay Advisory Services Inc. acquired a new stake in shares of Elevance Health in the 4th quarter valued at $31,000. J.Safra Asset Management Corp acquired a new stake in shares of Elevance Health in the 4th quarter valued at $32,000. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA purchased a new stake in shares of Elevance Health during the 4th quarter worth $38,000. Finally, Main Street Group LTD purchased a new stake in Elevance Health during the 1st quarter worth about $39,000. 89.24% of the stock is owned by institutional investors and hedge funds.

Elevance Health Stock Performance NYSE:ELV opened at $397.77 on Thursday. Elevance Health, Inc. has a 1-year low of $274.84 and a 1-year high of $436.24. The firm has a market cap of $86.26 billion, a PE ratio of 17.68, a P/E/G ratio of 2.24 and a beta of 0.68. The firm has a 50 day simple moving average of $396.58 and a 200-day simple moving average of $357.65. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.52 and a quick ratio of 1.52.

Elevance Health (NYSE:ELV – Get Free Report) last posted its quarterly earnings data on Wednesday, July 15th. The company reported $7.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.21 by $1.24. Elevance Health had a return on equity of 14.64% and a net margin of 2.47%.The business had revenue of $49.83 billion for the quarter, compared to analysts’ expectations of $48.88 billion. During the same quarter last year, the firm earned $8.84 earnings per share. The business’s revenue was up .8% on a year-over-year basis. On average, equities analysts expect that Elevance Health, Inc. will post 27.07 EPS for the current year.

Elevance Health Dividend Announcement The company also recently announced a quarterly dividend, which will be paid on Friday, September 25th. Investors of record on Thursday, September 10th will be issued a $1.72 dividend. The ex-dividend date is Thursday, September 10th. This represents a $6.88 dividend on an annualized basis and a yield of 1.7%. Elevance Health’s dividend payout ratio (DPR) is presently 30.58%.

Wall Street Analyst Weigh In Several brokerages have recently issued reports on ELV. Mizuho upped their target price on shares of Elevance Health from $435.00 to $465.00 and gave the company an “outperform” rating in a report on Monday, June 8th. Leerink Partners lifted their target price on Elevance Health from $364.00 to $395.00 and gave the company a “market perform” rating in a research note on Friday, July 17th. Morgan Stanley boosted their price target on shares of Elevance Health from $352.00 to $404.00 and gave the stock an “equal weight” rating in a research note on Thursday, June 4th. Royal Bank Of Canada dropped their price objective on Elevance Health from $439.00 to $424.00 and set a “sector perform” rating on the stock in a report on Thursday, July 16th. Finally, Barclays lowered their target price on shares of Elevance Health from $480.00 to $457.00 and set an “overweight” rating on the stock in a research report on Thursday, July 16th. Fifteen equities research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $440.90.

Check Out Our Latest Stock Report on ELV

Insider Buying and Selling at Elevance Health In other news, Director Robert L. Dixon, Jr. sold 151 shares of Elevance Health stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $401.77, for a total value of $60,667.27. Following the transaction, the director directly owned 10,734 shares of the company’s stock, valued at $4,312,599.18. The trade was a 1.39% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. 0.34% of the stock is owned by corporate insiders.

About Elevance Health (Free Report)

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.

Recommended Stories Five stocks we like better than Elevance Health GE Vernova’s AI Power Boom Faces a Profit Test Cardinal Health Earnings: Can Perfection Get Priced In Twice? Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand Legacy Jet Builders Stall While Embraer Accelerates to New Highs Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV – Free Report).

Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEBallast Inc. Acquires New Stake in Citigroup Inc. $C

NEXT HEADLINE »UnitedHealth Group Incorporated $UNH Shares Purchased by Ballast Inc.

Posted by Defense World Staff on Aug 1st, 2026

Axiom Investment Management LLC bought a new position in Elevance Health, Inc. (NYSE:ELV – Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 1,853 shares of the company’s stock, valued at approximately $542,000.

Other institutional investors have also recently made changes to their positions in the company. M&T Bank Corp lifted its stake in shares of Elevance Health by 160.4% during the fourth quarter. M&T Bank Corp now owns 50,486 shares of the company’s stock worth $17,698,000 after buying an additional 31,101 shares during the period. Solidarity Wealth LLC purchased a new position in Elevance Health in the 4th quarter worth $1,433,000. Manning & Napier Advisors LLC lifted its position in Elevance Health by 1,423.1% during the 4th quarter. Manning & Napier Advisors LLC now owns 368,426 shares of the company’s stock worth $129,152,000 after acquiring an additional 344,237 shares during the period. Aberdeen Group plc grew its stake in Elevance Health by 6.1% during the 4th quarter. Aberdeen Group plc now owns 288,976 shares of the company’s stock valued at $101,301,000 after purchasing an additional 16,540 shares during the last quarter. Finally, Assetmark Inc. grew its stake in Elevance Health by 21.8% during the 4th quarter. Assetmark Inc. now owns 105,688 shares of the company’s stock valued at $37,049,000 after purchasing an additional 18,913 shares during the last quarter. Institutional investors own 89.24% of the company’s stock.

Elevance Health Stock Performance ELV opened at $375.44 on Friday. The company has a quick ratio of 1.52, a current ratio of 1.52 and a debt-to-equity ratio of 0.68. The company has a market cap of $81.42 billion, a price-to-earnings ratio of 16.69, a PEG ratio of 2.17 and a beta of 0.67. Elevance Health, Inc. has a 52-week low of $273.71 and a 52-week high of $436.24. The firm’s fifty day simple moving average is $397.01 and its two-hundred day simple moving average is $356.81.

Elevance Health (NYSE:ELV – Get Free Report) last released its earnings results on Wednesday, July 15th. The company reported $7.45 EPS for the quarter, topping analysts’ consensus estimates of $6.21 by $1.24. The business had revenue of $49.83 billion during the quarter, compared to analysts’ expectations of $48.88 billion. Elevance Health had a net margin of 2.47% and a return on equity of 14.64%. The company’s quarterly revenue was up .8% on a year-over-year basis. During the same quarter in the previous year, the company earned $8.84 earnings per share. Equities analysts anticipate that Elevance Health, Inc. will post 27.04 earnings per share for the current fiscal year.

Elevance Health Announces Dividend The company also recently announced a quarterly dividend, which will be paid on Friday, September 25th. Shareholders of record on Thursday, September 10th will be issued a dividend of $1.72 per share. The ex-dividend date of this dividend is Thursday, September 10th. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.8%. Elevance Health’s dividend payout ratio is presently 30.58%.

Wall Street Analyst Weigh In A number of brokerages recently commented on ELV. Guggenheim upped their target price on Elevance Health from $399.00 to $455.00 and gave the company a “buy” rating in a research report on Thursday, July 16th. Truist Financial raised their target price on shares of Elevance Health from $450.00 to $475.00 and gave the stock a “buy” rating in a report on Tuesday, July 14th. Evercore restated a “hold” rating on shares of Elevance Health in a research report on Tuesday, May 19th. Raymond James Financial set a $450.00 price objective on Elevance Health in a report on Tuesday, July 7th. Finally, Barclays dropped their target price on Elevance Health from $480.00 to $457.00 and set an “overweight” rating on the stock in a report on Thursday, July 16th. Fifteen investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $440.90.

Check Out Our Latest Research Report on Elevance Health

Insider Buying and Selling at Elevance Health In other news, Director Robert L. Dixon, Jr. sold 151 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $401.77, for a total value of $60,667.27. Following the transaction, the director owned 10,734 shares in the company, valued at $4,312,599.18. This trade represents a 1.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.34% of the stock is currently owned by company insiders.

About Elevance Health (Free Report)

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.

Read More Five stocks we like better than Elevance Health Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case Apple’s Record Quarter Could Not Outrun Its Guidance Problem McKesson’s Compounding Keeps Adding Up Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV – Free Report).

Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINE13,379 Shares in Procter & Gamble Company (The) $PG Acquired by Alpine Woods Capital Investors LLC

Posted by Defense World Staff on Jul 29th, 2026

Amundi increased its stake in shares of Elevance Health, Inc. (NYSE:ELV – Free Report) by 145.7% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,693,664 shares of the company’s stock after purchasing an additional 1,597,497 shares during the period. Amundi owned 1.24% of Elevance Health worth $788,570,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ELV. Wellington Management Group LLP boosted its position in Elevance Health by 25.2% during the fourth quarter. Wellington Management Group LLP now owns 8,289,976 shares of the company’s stock worth $2,906,051,000 after acquiring an additional 1,668,679 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Elevance Health by 27.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,446,185 shares of the company’s stock valued at $2,610,261,000 after acquiring an additional 1,607,274 shares during the last quarter. Artisan Partners Limited Partnership lifted its stake in shares of Elevance Health by 10.0% during the 4th quarter. Artisan Partners Limited Partnership now owns 5,032,751 shares of the company’s stock worth $1,764,231,000 after purchasing an additional 455,946 shares during the period. First Eagle Investment Management LLC lifted its stake in shares of Elevance Health by 0.6% during the 4th quarter. First Eagle Investment Management LLC now owns 4,022,874 shares of the company’s stock worth $1,410,219,000 after purchasing an additional 24,271 shares during the period. Finally, Invesco Ltd. boosted its holdings in shares of Elevance Health by 50.3% during the fourth quarter. Invesco Ltd. now owns 3,903,878 shares of the company’s stock worth $1,368,505,000 after purchasing an additional 1,306,390 shares during the last quarter. Hedge funds and other institutional investors own 89.24% of the company’s stock.

Wall Street Analyst Weigh In Several research firms recently weighed in on ELV. Cantor Fitzgerald increased their target price on Elevance Health from $400.00 to $450.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 7th. Mizuho lifted their price target on Elevance Health from $435.00 to $465.00 and gave the company an “outperform” rating in a report on Monday, June 8th. Royal Bank Of Canada dropped their price objective on shares of Elevance Health from $439.00 to $424.00 and set a “sector perform” rating for the company in a research note on Thursday, July 16th. UBS Group raised their target price on shares of Elevance Health from $400.00 to $460.00 and gave the stock a “buy” rating in a research report on Friday, May 22nd. Finally, Guggenheim boosted their target price on shares of Elevance Health from $399.00 to $455.00 and gave the company a “buy” rating in a report on Thursday, July 16th. Fifteen investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $440.90.

Get Our Latest Research Report on ELV

Elevance Health Trading Up 1.9% Shares of ELV opened at $385.67 on Wednesday. The stock’s 50-day moving average is $398.05 and its two-hundred day moving average is $356.65. The stock has a market cap of $83.64 billion, a PE ratio of 17.14, a P/E/G ratio of 2.18 and a beta of 0.67. Elevance Health, Inc. has a 12 month low of $273.71 and a 12 month high of $436.24. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.52 and a quick ratio of 1.52.

Elevance Health (NYSE:ELV – Get Free Report) last issued its earnings results on Wednesday, July 15th. The company reported $7.45 earnings per share for the quarter, topping the consensus estimate of $6.21 by $1.24. The company had revenue of $49.83 billion during the quarter, compared to the consensus estimate of $48.88 billion. Elevance Health had a return on equity of 14.64% and a net margin of 2.47%.The company’s revenue was up .8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $8.84 earnings per share. Equities analysts forecast that Elevance Health, Inc. will post 27.04 earnings per share for the current fiscal year.

Elevance Health Announces Dividend The firm also recently announced a quarterly dividend, which will be paid on Friday, September 25th. Stockholders of record on Thursday, September 10th will be given a dividend of $1.72 per share. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date of this dividend is Thursday, September 10th. Elevance Health’s payout ratio is presently 30.58%.

Insider Activity at Elevance Health In related news, Director Robert L. Dixon, Jr. sold 151 shares of the business’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $401.77, for a total value of $60,667.27. Following the transaction, the director owned 10,734 shares in the company, valued at approximately $4,312,599.18. The trade was a 1.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.34% of the company’s stock.

Elevance Health Profile (Free Report)

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.

Further Reading Five stocks we like better than Elevance Health These 3 Stocks Have Soared in 2026—Can They Keep Climbing? Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction Chips & Clips: Memory Tariffs Rewire Tech Supply Chains Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV – Free Report).

Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEThermo Fisher Scientific Inc. $TMO Shares Bought by Amundi

NEXT HEADLINE »Amundi Has $844.98 Million Holdings in NextEra Energy, Inc. $NEE

Posted by Defense World Staff on Jul 24th, 2026

Bessemer Group Inc. lessened its stake in shares of Elevance Health, Inc. (NYSE:ELV – Free Report) by 97.0% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,297 shares of the company’s stock after selling 138,897 shares during the quarter. Bessemer Group Inc.’s holdings in Elevance Health were worth $1,258,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of ELV. Bank of New York Mellon Corp grew its stake in Elevance Health by 18.1% during the first quarter. Bank of New York Mellon Corp now owns 2,845,280 shares of the company’s stock worth $832,956,000 after buying an additional 436,576 shares during the last quarter. Signet Financial Management LLC raised its stake in shares of Elevance Health by 3.5% in the first quarter. Signet Financial Management LLC now owns 837 shares of the company’s stock valued at $245,000 after acquiring an additional 28 shares during the last quarter. Checchi Capital Advisers LLC boosted its holdings in shares of Elevance Health by 11.3% in the 1st quarter. Checchi Capital Advisers LLC now owns 2,194 shares of the company’s stock worth $642,000 after acquiring an additional 222 shares in the last quarter. AMG National Trust Bank boosted its holdings in shares of Elevance Health by 84.7% in the 1st quarter. AMG National Trust Bank now owns 7,300 shares of the company’s stock worth $2,137,000 after acquiring an additional 3,348 shares in the last quarter. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management grew its position in Elevance Health by 36.8% during the 1st quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 2,480 shares of the company’s stock worth $726,000 after acquiring an additional 667 shares during the last quarter. Institutional investors and hedge funds own 89.24% of the company’s stock.

Elevance Health Stock Down 2.7% Shares of ELV opened at $378.48 on Friday. The business’s fifty day moving average price is $399.00 and its two-hundred day moving average price is $356.37. The firm has a market capitalization of $82.08 billion, a price-to-earnings ratio of 16.82, a PEG ratio of 2.24 and a beta of 0.67. Elevance Health, Inc. has a 52 week low of $273.71 and a 52 week high of $436.24. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.52 and a current ratio of 1.52.

Elevance Health (NYSE:ELV – Get Free Report) last released its earnings results on Wednesday, July 15th. The company reported $7.45 earnings per share for the quarter, topping analysts’ consensus estimates of $6.21 by $1.24. The company had revenue of $49.83 billion during the quarter, compared to the consensus estimate of $48.88 billion. Elevance Health had a return on equity of 14.64% and a net margin of 2.47%.The firm’s quarterly revenue was up .8% on a year-over-year basis. During the same quarter in the previous year, the company posted $8.84 earnings per share. On average, analysts predict that Elevance Health, Inc. will post 27.08 earnings per share for the current year.

Elevance Health Announces Dividend The firm also recently announced a quarterly dividend, which will be paid on Friday, September 25th. Shareholders of record on Thursday, September 10th will be given a dividend of $1.72 per share. The ex-dividend date is Thursday, September 10th. This represents a $6.88 dividend on an annualized basis and a yield of 1.8%. Elevance Health’s dividend payout ratio is presently 30.58%.

Insider Activity In other news, Director Robert L. Dixon, Jr. sold 151 shares of the firm’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $401.77, for a total value of $60,667.27. Following the transaction, the director owned 10,734 shares of the company’s stock, valued at approximately $4,312,599.18. This trade represents a 1.39% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.34% of the company’s stock.

Analyst Ratings Changes Several brokerages have issued reports on ELV. UBS Group lifted their price objective on Elevance Health from $400.00 to $460.00 and gave the company a “buy” rating in a research report on Friday, May 22nd. The Goldman Sachs Group restated a “neutral” rating and set a $395.00 target price on shares of Elevance Health in a report on Thursday, July 16th. TD Cowen lifted their price target on Elevance Health from $400.00 to $465.00 and gave the company a “buy” rating in a report on Tuesday, July 14th. Jefferies Financial Group reduced their price target on shares of Elevance Health from $395.00 to $391.00 and set a “buy” rating on the stock in a research report on Monday, April 20th. Finally, Citigroup raised shares of Elevance Health to a “buy” rating in a report on Wednesday, April 29th. Fifteen equities research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat.com, Elevance Health has a consensus rating of “Moderate Buy” and an average target price of $440.90.

Get Our Latest Stock Analysis on Elevance Health

Elevance Health Company Profile (Free Report)

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.

See Also Five stocks we like better than Elevance Health Premium Retail’s Stress Test Is Separating Winners From Losers D-Wave Quantum or a Quantum ETF: Which Is the Better Bet? GE Vernova Just Sent a Mixed AI Signal to Investors Alphabet Crushed Earnings, But One Number Spooked the Market

Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEBank of Nova Scotia Cuts Stake in Arista Networks, Inc. $ANET

Acumen Wealth Advisors LLC decreased its stake in shares of Elevance Health, Inc. (NYSE: ELV) by 51.5% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,935 shares of the company's stock after selling 7,357 shares during the quarter. Acumen Wealth Advisors

Elevance Health (NYSE:ELV) raised its 2026 adjusted earnings outlook after second-quarter results came in ahead of management’s expectations, citing favorable benefit expense performance, disciplined cost management and improving execution across several major business lines.

President and CEO Gail Boudreaux said the company now expects 2026 adjusted diluted earnings per share of at least $27. Chief Financial Officer Mark Kaye said Elevance views at least $26 as the appropriate 2026 earnings baseline for modeling purposes and remains confident in returning to at least 12% adjusted EPS growth in 2027 off that higher baseline.

For the second quarter, Elevance reported adjusted diluted earnings per share of $7.45. Operating revenue was $49.8 billion, up 0.8% from a year earlier, driven by higher premium yields and product revenue, partly offset by lower health plan membership. The company ended the quarter with 44.9 million medical members, with the sequential decline attributed mainly to a known fee-based customer transition and attrition in its individual ACA and Medicaid businesses.

Medicaid Remains a Key Focus as Margins Stay Under Pressure Management spent much of the call addressing Medicaid, where Boudreaux said the operating environment remains “dynamic.” Elevance maintained its full-year Medicaid operating margin outlook of approximately negative 1.75%, even as rate updates received during the quarter were stronger than anticipated.

Kaye said Medicaid cost drivers remain elevated and concentrated in previously identified areas, including behavioral health, specialty pharmacy, outpatient surgery and emergency department utilization. He said the company is not seeing a new “stepwise acuity reset,” adding that membership and acuity remain broadly aligned with assumptions. Instead, incremental pressure is increasingly tied to utilization among members who remain in the program.

Management reiterated that 2026 is expected to be the trough year for Medicaid margins, with improvement over time supported by better rate alignment and the maturation of care management actions. Kaye said the second-half Medicaid margin profile is expected to improve from the second quarter, supported by favorable July 1 rate activity and continued execution against cost pressures.

Boudreaux also said Elevance recently reached a mutual agreement with the District of Columbia to exit the D.C. Medicaid market. She said the company expects to exit additional Medicaid markets over the next 12 to 18 months where it does not see a path to sustainable performance. Executives did not identify the additional markets or provide sizing for potential exits.

Medicare Advantage and ACA Help Drive Second-Quarter Outperformance Elevance said Medicare Advantage results were stronger than expected and contributed to the company’s quarterly outperformance. Boudreaux said deliberate actions taken to reposition the portfolio — including disciplined plan design and a more focused mix of dual-eligible special needs plans and HMO products — are translating into stronger performance.

The company said it remains on track for at least a 2% operating margin in Medicare Advantage this year. Aimée Dailey, president of Government Health Benefits, said Elevance’s 2027 bids were developed with a prudent view of trend and a continued focus on sustainable margin improvement. She said the company continues to believe underlying medical cost trend is outpacing program funding.

In the individual ACA business, management said performance is developing broadly in line with how the year was priced and planned. Kaye said second-quarter favorability reflected more pronounced seasonality tied to a higher mix of bronze plans, as well as favorable final 2025 CMS risk adjustment results relative to prior estimates. However, he said Elevance is not extrapolating that favorability into 2026 and is reestablishing much of the prior-year favorability in its current-year risk adjustment accrual.

Kaye said member retention in ACA remains modestly ahead of expectations and that Elevance now expects to end 2026 with at least 1 million individual ACA members.

Commercial Business and Carelon Remain Growth Priorities In commercial health benefits, management said performance was in line with expectations, with cost trend remaining elevated but consistent with the company’s pricing approach. Morgan Kendrick, president of Commercial Health Benefits, said the market remains focused on affordability and simplicity, and that Elevance’s assets are resonating with employers.

Kendrick said the company’s fee-based and self-funded commercial businesses are performing well, including both local market and national account activity. He said Elevance had a record year in national accounts for 2026 and that its pipeline for 2027 is nearly as large. He also said some customers that left the company in prior years have returned.

Carelon also remains a focus of Elevance’s growth strategy. Boudreaux said CareBridge, which extends Carelon’s whole-health model into the home, can generate medical savings in the mid-teens for members and is being expanded into new markets. She also said Carelon behavioral health programs have delivered average cost savings of 10% through stronger member engagement and fewer adverse events.

Company Plans One-Time Investments From Non-Recurring Benefit Kaye said Elevance recorded a net below-the-line benefit of $0.80 per share in the quarter, primarily related to valuation adjustments within net investment income. Management said it plans to use that non-recurring benefit to fund one-time investments in the second half of the year.

Boudreaux said the investments are focused on strengthening medical cost management, member engagement, provider connectivity, operating efficiency and Carelon’s integrated capabilities. She said the company is using data and AI-enabled tools to identify medical cost pressures earlier and respond more quickly with targeted clinical, network, payment integrity and operating actions.

Executives emphasized that these incremental investments are one-time and will not recur in 2027. Kaye said the company’s 2026 outlook already included approximately $0.75 per share of targeted investment spending that is part of the ongoing run rate, separate from the new $0.80 per share of accelerated investments funded by the below-the-line benefit.

Cash Flow Outlook Raised; CMS Matter Closed Elevance reported second-quarter operating cash flow of $1.9 billion. Kaye said cash flow benefited from strong operating performance and the timing of a state Medicaid pass-through payment received in the quarter and remitted in July. The company raised its full-year operating cash flow outlook to at least $6 billion.

Days in claims payable were 45.4 days as of June 30, up 2.9 days from a year earlier. Kaye said the company remains confident in its reserving levels and described its reserve posture as consistent and prudent.

Kaye also said Elevance made an initial remittance of $342 million to CMS in the second quarter related to a matter discussed on the prior quarter’s call. He said the estimate of potential total financial exposure remains unchanged. As of July 9, Elevance completed all steps required by CMS and subsequently received written confirmation that sanctions will not be imposed and the matter is closed.

Boudreaux closed the call by saying Elevance’s confidence in 2027 is based on the breadth of the enterprise rather than any single line of business. She pointed to commercial pricing discipline, Medicare Advantage portfolio actions, ACA execution, expected Medicaid improvement, Carelon growth, operating efficiency and capital deployment as contributors to the company’s earnings path.

About Elevance Health (NYSE:ELV) Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

© fizkes / Shutterstock.com

A letter arrives in late summer. The hospital system a retiree has used for 20 years, the one that houses her cardiologist and her oncologist and her primary care doctor, will no longer accept her Medicare Advantage plan as of a date printed near the bottom of page two. She had made no changes on her end. Her plan stayed in place on paper. The contract between the two of them ended, and she found out by mail.

This scenario has become common enough that it is worth understanding before the next Annual Enrollment Period. If you are on Original Medicare with a Medigap policy, this article is largely not about you. If you are on a Medicare Advantage plan, or considering one at 65, the mechanic below is the one that will most likely bite.

Why Hospitals Are Walking Away Mid-Contract Hospital systems and physician groups across the country have terminated or declined to renew Medicare Advantage contracts over the past two years, citing three recurring problems: prior-authorization friction, claim denials, and slow or low reimbursement from MA plans. In plain terms, hospitals say they treat the patient, then spend months arguing with the insurer over whether the care was necessary and how much of it will be paid.

The insurer side of the ledger explains the pressure. Elevance Health (NYSE:ELV | ELV Price Prediction), one of the largest managed care companies in the country, reported that elevated medical costs in government businesses contributed to an increased benefit expense ratio in its most recent quarter. When insurers face rising costs on MA members, they tighten authorization rules and push back harder on hospital bills. Hospitals absorb the delay, then decide the contract is not worth renewing.

The result lands in a patient’s mailbox.

What the Letter Actually Means A mid-year network termination leaves your Medicare Advantage plan in place. Your plan continues, but the hospital or physician group inside it does not. Once the termination date passes, visits to that provider are treated as out-of-network. On most HMO-style MA plans, out-of-network care is not covered at all except in emergencies. On PPO-style plans, it is covered at a higher cost share, and out-of-network spending typically does not count toward the in-network out-of-pocket maximum.

The advertised in-network cap on your plan stops protecting you the moment your hospital leaves the network.

The Protections That Actually Apply Federal continuity-of-care rules require Medicare Advantage plans to allow certain patients, typically those in active treatment for serious conditions, pregnancy, or end-stage illness, to continue seeing a departing provider at in-network cost sharing for a transitional period. The plan sets the exact terms, and the patient must request it. It is not automatic.

A Special Enrollment Period may open when a plan experiences a significant network change, which lets the member switch to another MA plan or return to Original Medicare outside the usual October-to-December window. CMS decides case by case whether an SEP applies, so the letter from the plan is the first place to check. If it grants an SEP, use it.

The Switch-Back Trap Returning to Original Medicare sounds like the clean fix. It is not that simple after the first six months of Part B enrollment. Outside that federal Medigap open enrollment window, a Medigap insurer in most states can medically underwrite, charge more, or deny coverage entirely. A handful of states, including New York, Connecticut, Massachusetts, and Maine, offer broader guaranteed-issue rights. Everywhere else, a 72-year-old with a cardiac history who wants to leave her MA plan may find Medigap effectively closed to her.

This is the cost of the original MA decision that the $0 premium never advertised. Getting in is easy. Getting out clean is not. (For retirees mapping the broader landscape of surprise Medicare costs, the Medicare’s Hidden Bills report walks through the categories worth stress-testing before enrollment.)

What To Do Now Read every plan letter the month it arrives. Network termination notices are legally required, but they look like junk mail. The effective date on page two is the only date that matters. Re-verify your provider network every Annual Enrollment Period, which runs October 15 to December 7. Do not assume last year’s network carries forward. Call the hospital’s billing office directly and ask which MA contracts they will honor for the coming plan year, not just which they accept today. If you are still inside your six-month Medigap open enrollment window, price a Medigap Plan G or Plan N against your current MA plan before that window closes. The underwriting protection you have right now expires once, and never returns in most states. With the 2026 Social Security COLA at 2.8%, most retirees have little slack in their monthly budget for an out-of-network hospital bill they did not plan for. The letter in the mailbox is the warning. The action window closes fast.

Contact [email protected] for any questions or corrections.

Elevance Health, Inc. (ELV) Q2 2026 Earnings Call Transcript

Key Takeaways ELV topped Q2 EPS and revenue estimates as premium yields and CarelonRx sales supported results.Elevance Health raised 2026 adjusted EPS guidance to at least $27.00 and lifted operating cash flow outlook.ELV grew operating cash flow to $6.2B as cash rose, while medical membership declined 1.5% year over year. Elevance Health, Inc. (ELV - Free Report) reported second-quarter 2026 adjusted earnings per share (EPS) of $7.45, which surpassed the Zacks Consensus Estimate by 20.6%. However, the bottom line declined 15.7% year over year.

Operating revenues advanced 0.8% year over year to $49.8 billion. The top line beat the consensus mark by 2.9%.

The quarterly results were primarily driven by higher premium yields in the Health Benefits segment and increased CarelonRx product revenues. The upside was partly offset by a decline in overall medical membership and an elevated expense level.

ELV’s Q2 Operational UpdateAs of June 30, 2026, Medical membership of Elevance Health was around 44.9 million, which dipped 1.5% year over year. The decrease was due to the expected loss of some commercial fee-based customers and a decline in Individual ACA and Medicaid membership. The reported figure beat the Zacks Consensus Estimate of 44.8 million and our estimate of 44.5 million.

Premiums totaled $41.3 billion in the quarter under review, which remained flat year over year and surpassed our estimate of $39.3 billion. Product revenues grew 3.7% year over year to $6.3 billion, marginally missing the Zacks Consensus Estimate by 0.9% and our estimate by 0.5%.

Net investment income rose 44.9% year over year to $704 million. The Adjusted operating margin of 3.6% deteriorated 140 basis points (bps) year over year.

Total expenses escalated 2.2% year over year to $48.5 billion in the second quarter, higher than our estimate of $46.7 billion. The year-over-year increase was due to higher cost of products sold, operating expenses and interest expenses.

The operating expense ratio was 11.1%, which increased 100 bps year over year. The benefit expense ratio increased 80 bps year over year to 89.7%.

Q2 Segmental Results of ELVHealth Benefits

The unit recorded operating revenues of $42.7 billion in the second quarter, which rose 2.7% year over year and beat the Zacks Consensus Estimate of $41.2 billion as well as our estimate of $40.7 billion. The segment benefited from increased premium yields.

The unit recorded an operating gain of $0.9 billion, which fell 43.8% year over year. It also missed the consensus mark of $1 billion. The operating margin deteriorated 170 basis points year over year to 2.1%.

Carelon

The segment’s operating revenues rose 6.1% year over year to $19.2 billion in the quarter under review, beating the Zacks Consensus Estimate of $18.4 billion and our estimate of $18.3 billion. The year-over-year increase was driven by higher CarelonRx product revenues and the scaling of risk-based capabilities in Carelon Services.

The unit’s operating gain of $0.9 billion was up 1% year over year, reflecting better profitability in specialty pharmacy. The operating margin deteriorated 30 bps year over year to 4.9%.

Corporate & Other

Operating revenues amounted to $6 million. The unit incurred an operating loss of $81 million, wider than the prior-year quarter’s loss of $71 million.

ELV’s Financial Details (As of June 30, 2026)Elevance Health exited the second quarter with cash and cash equivalents of $10.2 billion, which advanced 7.8% from the 2025-end level. Total assets of $126.4 billion increased 4.1% from the figure as of 2025-end.

Long-term debt, less the current portion, amounted to $30.7 billion and fell 0.4% from the figure as of Dec. 31, 2025. There were no short-term borrowings at the end of the second quarter, while the current portion of the long-term debt amounted to $375 million.

Total equity of $45 billion was up 2.3% from the 2025-end level.

Elevance Health generated net cash flow from operations of $6.2 billion at the end of the second quarter of 2026. The figure rose from the prior-year figure of $3.1 billion.

ELV: Capital Deployment UpdateElevance Health bought back shares worth $0.7 million in the second quarter. It had a leftover capacity of around $5.3 billion under its share buyback authorization as of June 30, 2026.

Elevance Health paid a quarterly dividend of $1.72 per share, adding up to a cash distribution worth $373 million.

ELV’s Revised 2026 OutlookThe company now expects adjusted EPS to be at least $27.00, up from the previous guidance of at least $26.75.

The operating margin for the Health Benefits segment was earlier estimated to witness a decrease of 50-25 bps from the 2025 reported figure. Also, the operating margin for CarelonRx was expected to see a 25-0 bps decline, while the same for Carelon Services was estimated to witness an increase of 0-25 bps.

Management had earlier projected operating revenues to witness a low-single-digit decline in 2026 from the 2025 level. Premium revenues were estimated to witness a mid-single-digit decline from the 2025 level. Medical enrollment was forecasted to be between 43.2 million and 43.9 million in 2026.

Net investment income was expected to be $1.9 billion. Interest expenses were forecasted to be $1.5 billion in 2026, while operating cash flow guidance raised to at least $6.0 billion. Diluted shares are estimated to be 219-220 million.

ELV’s Zacks Rank & Other Key PicksELV currently carries a Zacks Rank #2 (Buy).

Some other top-ranked stocks in the broader medical space are UnitedHealth Group Incorporated (UNH - Free Report) , CVS Health Corporation (CVS - Free Report) and Pediatrix Medical Group, Inc. (MD - Free Report) , each currently carrying a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The Zacks Consensus Estimate for UnitedHealth Group’s second quarter 2026 earnings is pegged at $4.87 per share, which has witnessed one upward revision in the past 60 days, with no movement in the opposite direction. It beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 0.8%. The consensus estimates for UNH’s second quarter2026 revenues is pinned at $110.05 billion.

The Zacks Consensus Estimate for CVS Health’s second quarter 2026 earnings is pegged at $1.87 per share, which has witnessed two upward revisions in the past 60 days, with no movement in the opposite direction. It beat earnings estimates in each of the trailing four quarters, with the average surprise being 16.8% The consensus estimates for CVS’ second quarter 2026 revenues is pinned at $100.18 billion, implying 1.3% year-over-year growth.

The Zacks Consensus Estimate for Pediatrix Medical’s second quarter 2026 earnings is pegged at 57 cents per share, indicating a 7.6% year-over-year increase. It beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 21.3%. The consensus estimate for MD’s second quarter 2026 revenues is pinned at $ 477.34 million, implying 1.8% year-over-year growth.

This ETF Is Proof That the Healthcare Rebound Is RealElevance Health NYSE: ELV raised its 2026 adjusted earnings outlook after second-quarter results came in ahead of management’s expectations, citing favorable benefit expense performance, disciplined cost management and improving execution across several major business lines.

President and CEO Gail Boudreaux said the company now expects 2026 adjusted diluted earnings per share of at least $27. Chief Financial Officer Mark Kaye said Elevance views at least $26 as the appropriate 2026 earnings baseline for modeling purposes and remains confident in returning to at least 12% adjusted EPS growth in 2027 off that higher baseline.

Get Elevance Health alerts:

Getting Defensive: 3 Dividend Payers Reporting Strong Q3 EarningsFor the second quarter, Elevance reported adjusted diluted earnings per share of $7.45. Operating revenue was $49.8 billion, up 0.8% from a year earlier, driven by higher premium yields and product revenue, partly offset by lower health plan membership. The company ended the quarter with 44.9 million medical members, with the sequential decline attributed mainly to a known fee-based customer transition and attrition in its individual ACA and Medicaid businesses.

Medicaid Remains a Key Focus as Margins Stay Under Pressure Management spent much of the call addressing Medicaid, where Boudreaux said the operating environment remains “dynamic.” Elevance maintained its full-year Medicaid operating margin outlook of approximately negative 1.75%, even as rate updates received during the quarter were stronger than anticipated.

Why Centene Stock Dropped 40% — And Whether It's a Buy NowKaye said Medicaid cost drivers remain elevated and concentrated in previously identified areas, including behavioral health, specialty pharmacy, outpatient surgery and emergency department utilization. He said the company is not seeing a new “stepwise acuity reset,” adding that membership and acuity remain broadly aligned with assumptions. Instead, incremental pressure is increasingly tied to utilization among members who remain in the program.

Management reiterated that 2026 is expected to be the trough year for Medicaid margins, with improvement over time supported by better rate alignment and the maturation of care management actions. Kaye said the second-half Medicaid margin profile is expected to improve from the second quarter, supported by favorable July 1 rate activity and continued execution against cost pressures.

Boudreaux also said Elevance recently reached a mutual agreement with the District of Columbia to exit the D.C. Medicaid market. She said the company expects to exit additional Medicaid markets over the next 12 to 18 months where it does not see a path to sustainable performance. Executives did not identify the additional markets or provide sizing for potential exits.

Medicare Advantage and ACA Help Drive Second-Quarter Outperformance Elevance said Medicare Advantage results were stronger than expected and contributed to the company’s quarterly outperformance. Boudreaux said deliberate actions taken to reposition the portfolio — including disciplined plan design and a more focused mix of dual-eligible special needs plans and HMO products — are translating into stronger performance.

The company said it remains on track for at least a 2% operating margin in Medicare Advantage this year. Aimée Dailey, president of Government Health Benefits, said Elevance’s 2027 bids were developed with a prudent view of trend and a continued focus on sustainable margin improvement. She said the company continues to believe underlying medical cost trend is outpacing program funding.

In the individual ACA business, management said performance is developing broadly in line with how the year was priced and planned. Kaye said second-quarter favorability reflected more pronounced seasonality tied to a higher mix of bronze plans, as well as favorable final 2025 CMS risk adjustment results relative to prior estimates. However, he said Elevance is not extrapolating that favorability into 2026 and is reestablishing much of the prior-year favorability in its current-year risk adjustment accrual.

Kaye said member retention in ACA remains modestly ahead of expectations and that Elevance now expects to end 2026 with at least 1 million individual ACA members.

Commercial Business and Carelon Remain Growth Priorities In commercial health benefits, management said performance was in line with expectations, with cost trend remaining elevated but consistent with the company’s pricing approach. Morgan Kendrick, president of Commercial Health Benefits, said the market remains focused on affordability and simplicity, and that Elevance’s assets are resonating with employers.

Kendrick said the company’s fee-based and self-funded commercial businesses are performing well, including both local market and national account activity. He said Elevance had a record year in national accounts for 2026 and that its pipeline for 2027 is nearly as large. He also said some customers that left the company in prior years have returned.

Carelon also remains a focus of Elevance’s growth strategy. Boudreaux said CareBridge, which extends Carelon’s whole-health model into the home, can generate medical savings in the mid-teens for members and is being expanded into new markets. She also said Carelon behavioral health programs have delivered average cost savings of 10% through stronger member engagement and fewer adverse events.

Company Plans One-Time Investments From Non-Recurring Benefit Kaye said Elevance recorded a net below-the-line benefit of $0.80 per share in the quarter, primarily related to valuation adjustments within net investment income. Management said it plans to use that non-recurring benefit to fund one-time investments in the second half of the year.

Boudreaux said the investments are focused on strengthening medical cost management, member engagement, provider connectivity, operating efficiency and Carelon’s integrated capabilities. She said the company is using data and AI-enabled tools to identify medical cost pressures earlier and respond more quickly with targeted clinical, network, payment integrity and operating actions.

Executives emphasized that these incremental investments are one-time and will not recur in 2027. Kaye said the company’s 2026 outlook already included approximately $0.75 per share of targeted investment spending that is part of the ongoing run rate, separate from the new $0.80 per share of accelerated investments funded by the below-the-line benefit.

Cash Flow Outlook Raised; CMS Matter Closed Elevance reported second-quarter operating cash flow of $1.9 billion. Kaye said cash flow benefited from strong operating performance and the timing of a state Medicaid pass-through payment received in the quarter and remitted in July. The company raised its full-year operating cash flow outlook to at least $6 billion.

Days in claims payable were 45.4 days as of June 30, up 2.9 days from a year earlier. Kaye said the company remains confident in its reserving levels and described its reserve posture as consistent and prudent.

Kaye also said Elevance made an initial remittance of $342 million to CMS in the second quarter related to a matter discussed on the prior quarter’s call. He said the estimate of potential total financial exposure remains unchanged. As of July 9, Elevance completed all steps required by CMS and subsequently received written confirmation that sanctions will not be imposed and the matter is closed.

Boudreaux closed the call by saying Elevance’s confidence in 2027 is based on the breadth of the enterprise rather than any single line of business. She pointed to commercial pricing discipline, Medicare Advantage portfolio actions, ACA execution, expected Medicaid improvement, Carelon growth, operating efficiency and capital deployment as contributors to the company’s earnings path.

About Elevance Health NYSE: ELVElevance Health, Inc NYSE: ELV is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company's strategic focus on integrated health care and benefit delivery.

Elevance's core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Elevance Health Right Now?Before you consider Elevance Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elevance Health wasn't on the list.

While Elevance Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Elevance Health on Wednesday, July 15, 2026, reported second quarter net income of $1.45 billion as medical costs fell in some health plans, triggering an improved outlook for the rest of the year. In this photo, Elevance President and CEO Health Gail Boudreaux testifies at a House Committee on Energy and Commerce Subcommittee on Health hearing on lowering health care costs at the Capitol, Thursday, Jan. 22, 2026, in Washington. (AP Photo/Allison Robbert)

Copyright 2026 The Associated Press. All rights reserved.

Elevance Health reported second quarter net income of $1.45 billion as medical costs fell in some health plans, triggering an improved outlook for the rest of the year.

The health insurer raised its full year earnings outlook to “at least $20.10” per share compared to an earlier forecast of “at least $19.85” per share. The decision to issue a new outlook reflected "strong second quarter operating results,” the company said Wednesday in its report.

Elevance, which is the nation’s second-largest health insurer behind UnitedHealth Group’s UnitedHealthcare, is best known for its operation of Anthem brand Blue Cross and Blue Shield plans in 14 states. In addition, Elevance manages Medicaid via contracts with multiple states and also sells individual coverage under the Affordable Care Act, also known as Obamacare. The company also has a growing Carelon healthcare services business.

Elevance reported a net income of $1.46 billion, or $6.71 per share, which was down 16.6% compared to $1.74 billion, or $7.72 per share. The company said the results “results were supported by favorable benefit expense performance and an approximately $0.80 per share net below-the-line benefit.”

Like many of its rival health insurers, the company has been battling rising medical expenses from customers in its health plans. Wednesday’s results reflected costs that are still up with the company’s benefit expense ratio, which is the percentage of premium revenue that goes toward medical costs, eclipsing 89%.

“The benefit expense ratio of 89.7 percent increased 80 basis points year over year, driven by expected elevated medical cost trend in our Government businesses, partially offset by improved performance in Individual ACA compared to the prior year,” Elevance said in its earnings report. The company’s reference to “individual ACA” is the individual health insurance plans under the Affordable Care Act also known as Obamacare.

MORE FOR YOU

Health insurers historically want that benefit expense ratio in the mid to low 80s but that’s been largely unachievable for most plans for the last year or so in part because Americans, particularly older adults in Medicare Advantage plans, have a pent up demand for healthcare following the Covid-19 pandemic when many patients delayed treatment. Costs have continued to surge into this year, insurers have been reporting.

But Elevance chief executive Gail K. Boudreaux said the company’s “second quarter results exceeded” executives outlook and the decision to raise guidance was “supported by disciplined execution and improved operating performance across our diversified portfolio.”

“We are raising our 2026 adjusted (earnings per share) guidance to at least $27.00 and accelerating targeted investments in the capabilities that matter most: medical cost management, member experience, provider connectivity, operating efficiency, and Carelon’s value-based solutions,” Boudreaux said in a statement accompanying the Elevance earnings report. "These actions will strengthen how we operate, improve consistency over time, and reinforce our confidence in returning to at least 12% adjusted EPS growth in 2027 off our 2026 earnings baseline.”

Total revenue was up 1.4% to $50.47 billion in the quarter. “Operating revenue was $49.8 billion in the second quarter of 2026, an increase of $0.4 billion compared to the prior year quarter,” Elevance said in its report. “This was driven by higher premium yields in our health benefits segment and growth in CarelonRx product revenue, partially offset by anticipated declines in our Medicare Advantage, Medicaid, and Employer Group risk membership.”

Elevance ended the quarter with 44.9 million health plan members, which was down 1.5% compared to 45.6 million in the year-ago quarter.

15.7.2026 15:14, ELV

Americká zdravotní pojišťovna Elevance Health zveřejnila výsledky hospodaření za druhý kvartál roku 2026. Očištěný zisk na akcii ve výši 7,45 USD překonal průměrný analytický odhad 6,18 USD. Společnost zároveň zvýšila celoroční výhled tohoto ukazatele na minimálně 27,00 USD. Zvýšení výhledu však podle analytiků zaostalo za rozsahem překonání odhadů ve čtvrtletí a nenaplnilo vysoká očekávání investorů.

Výsledky společnosti Elevance Health (ELV) za 2Q 2026   2Q 2026 Konsensus 2Q 2026 2Q 2025 Výnosy (mld. USD) 49,83 48,75 49,42 Čistý zisk (mld. USD) 1,46 --  1,74 Očištěný zisk na akcii (EPS, USD/akcie) 7,45* 6,18 8,84 *Výsledek na úrovni zisku byl podpořen příznivým vývojem nákladů na zdravotní péči a čistým přínosem položek pod provozní úrovní ve výši přibližně 0,80 USD na akcii, mimo jiné díky vyšším výnosům z investic.

Výsledky za 2Q Provozní výnosy meziročně vzrostly o 0,8 % na 49,83 mld. USD. Výnosy se dají rozdělit následovně:

Předepsané pojistné meziročně stagnovalo na 41,28 mld. USD, nicméně překonalo konsensus ve výši 39,88 mld. USD. Výnosy z prodeje produktů vzrostly o 3,7 % na 6,26 mld. USD, mírně pod odhadem 6,34 mld. USD. Poplatky za služby zaznamenaly růst o 8,3 % na 2,28 mld. USD při očekávání 2,24 mld. USD.

Výnosy pojišťovacího segmentu Health Benefits vzrostly o 2,7 % na 42,72 mld. USD při očekávání 41,1 mld. USD. Provozní zisk segmentu však meziročně klesl o 42,6 % na 896 mil. USD a nedosáhl odhadu 1,04 mld. USD. Provozní marže segmentu činila 2,1 % oproti 3,8 % před rokem, přičemž trh očekával 2,37 %. Pokles ziskovosti odráží vyšší náklady na zdravotní péči a cílené investice.

Výnosy segmentu Carelon, který zahrnuje lékárenské a zdravotnické služby, vzrostly o 6 % na 19,2 mld. USD:

Divize CarelonRx zaznamenala růst o 5,7 % na 11,25 mld. USD při konsensu 10,73 mld. USD. Divize Carelon Services vykázala růst o 7,2 % na 7,98 mld. USD, což bylo nad očekáváním 7,46 mld. USD. Podíl nákladů na zdravotní péči meziročně vzrostl o 80 bazických bodů na 89,7 %, byl však pod odhadem trhu ve výši 90,1 %. Růst byl způsoben očekávanými zvýšenými náklady na zdravotní péči ve vládních programech, částečně kompenzovanými zlepšenou výkonností v individuálním pojištění ACA.

Počet zdravotně pojištěných osob meziročně klesl o 1,5 % na 44,95 mil., mírně pod odhadem 44,98 mil.

Výhled na rok 2026 Společnost zvýšila výhled na celý rok 2026 a nyní očekává očištěný zisk na akcii minimálně 27,00 USD, zatímco dříve počítala s hodnotou minimálně 26,75 USD. Konsensus trhu činil 26,85 USD.

Komentář CEO „Naše výsledky za druhý kvartál překonaly náš výhled, podpořeny disciplinovanou realizací a zlepšenou provozní výkonností napříč naším diverzifikovaným portfoliem. Zvyšujeme náš výhled očištěného zisku na akcii pro rok 2026 na minimálně 27,00 USD a urychlujeme cílené investice do klíčových oblastí, na kterých záleží nejvíce: řízení nákladů na zdravotní péči, zkušenost členů, propojení s poskytovateli péče, provozní efektivita a řešení společnosti Carelon založená na hodnotě. Tyto kroky posílí způsob našeho fungování, zlepší naši dlouhodobou konzistentnost a upevní naše přesvědčení o návratu k minimálně 12% růstu očištěného zisku na akcii v roce 2027 v porovnání s výchozí základnou zisků z roku 2026,“ uvedla generální ředitelka Gail K. Boudreaux.

Pohledy analytiků Analytik David Windley z Jefferies uvedl, že vzhledem k růstu akcií zdravotních pojišťoven od prvního čtvrtletí trhu pravděpodobně nebude stačit jen mírné překonání odhadů a mírné zvýšení výhledu. Poznamenal také, že vedení označuje vývoj nákladů v programu Medicaid za odpovídající obezřetnému celoročnímu výhledu, zdá se však, že tento vývoj částečně vymazal pozitivní překvapení v Medicare Advantage a individuálním pojištění.

Analytik Whit Mayo z Leerinku hodnotí výsledky za druhý kvartál jako solidní, přišly však s menším pozitivním překvapením u podílu nákladů na zdravotní péči, než trh očekával, a se slabšími výsledky segmentu Carelon. Překonání odhadů u zisku na akcii bylo podle něj podpořeno vyššími výnosy z investic a jednorázovými přínosy. Vzhledem k předchozímu růstu akcie považuje dnešní pokles za opodstatněný.

Analytik Andrew Mok z Barclays uvedl, že ačkoli se výsledky vyvíjejí pozitivně, společnost nepřinesla žádnou dodatečnou pozitivní zprávu ohledně programu Medicaid. Zvýšení výhledu zisku na akcii podle něj zaostalo za očekáváními.

Analytička Elizabeth Anderson z Evercore ISI poznamenala, že zisk segmentu Health Benefits byl v kvartále slabší kvůli investicím do růstu. Očekávání před zveřejněním výsledků byla podle ní vysoká a podíl nákladů na zdravotní péči mírně zaostal za očekáváními investorů, kteří počítali s překonáním konsensu o zhruba 30 a více bazických bodů.

Akcie Elevance Health Akcie Elevance Health (ELV) v předburzovní fázi obchodování oslabují o 7,45 % na 395 USD.

Akcie Elevance Health (ELV) před výsledky na 426,79 USD Ukazatel   Ukazatel   Kapitalizace (mld. USD) 92,7 P/E 17,5 Vývoj za letošní rok (%) +21,7 Očekávané P/E 15,9 52týdenní minimum (USD) 273,7 Prům. cílová cena (USD) 439,5 52týdenní maximum (USD) 436,2 Dividendový výnos (%) 1,6 Zdroj: Elevance Health, Bloomberg

Michal Bárta, Fio banka, a.s.

Elevance Health President and CEO Gail Boudreaux listens during a House Energy and Commerce Health Subcommittee hearing examining health insurance affordability and healthcare costs in... Purchase Licensing Rights, opens new tab Read more

CompaniesJuly 15 (Reuters) - Elevance Health (ELV.N), opens new tab ​raised its annual profit forecast after beating second-quarter ‌earnings estimates on Wednesday, as it looks to keep medical costs in check.

In April, the company said it has greater ​clarity on medical costs for the rest ​of the year as it leans on its ⁠efforts to keep them under control.

Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.

"Our second quarter ​results exceeded our outlook," Chief Executive Officer Gail ​Boudreaux said.

Elevance, which has greater exposure to commercial insurance and Medicaid plans for low-income Americans, has been withdrawing from underperforming ​Medicare Advantage markets for older adults.

Higher demand for ​healthcare services among members of government-funded plans has increased medical ‌expenses ⁠for health insurers.

For the quarter, the company reported a medical loss ratio, the percentage of premiums spent on medical care, of 89.7%. Analysts on average ​had expected ​a ratio ⁠of 90.15%, according to data compiled by LSEG.

The health insurer forecast annual adjusted ​profit to be at least $27 per share, ​compared ⁠with at least $26.75 per share projected earlier.

Analysts on average estimate an annual profit of $26.86 per share.

The company ⁠posted ​a quarterly adjusted profit of $7.45 ​per share, surpassing analysts' average estimate of $6.21.

Reporting by Sriparna Roy and ​Sneha S K in Bengaluru; Editing by Maju Samuel

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Key Takeaways Elevance is likely to see Q2 EPS of $6.18 on $48.45B in revenues, with both projected to decline.ELV may face pressure from lower premiums, membership declines and weaker Health Benefits results.Elevance's higher benefit expense ratio could weigh on profitability in the quarter. Elevance Health, Inc. (ELV - Free Report) is set to report its second-quarter 2026 results on July 15, 2026, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings is currently pegged at $6.18 per shareon revenues of $48.45 billion.

The second-quarter earnings estimate witnessed one downward revision and no upward revisions over the past 60 days. The bottom-line projection indicates a year-over-year decline of 30.1%. Also, the Zacks Consensus Estimate for quarterly revenues implies a year-over-year decrease of 2%.

Image Source: Zacks Investment Research

For 2026, the Zacks Consensus Estimate for Elevance’s revenues is pegged at $194.24 billion, implying a fall of 1.7% year over year. The consensus mark for 2026 EPS is pegged at $26.86, indicating an 11.3% year-over-year decrease.

Elevance’s earnings beat the consensus estimate in three of the trailing four quarters and missed once, with the average surprise being 10.6%. This is depicted in the figure below.

Q2 Earnings Whispers for ElevanceOur proven model does not conclusively predict an earnings beat for the company this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here.

ELV currently has an Earnings ESP of -0.42% and a Zacks Rank #2. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

What’s Shaping Elevance’s Q2 Results?The Zacks Consensus Estimate for product revenues indicates 4.7% growth from the year-ago period’s $6.04 billion. However, the consensus estimate for premiums indicates a 3.3% decrease from the year-ago period.

The consensus mark for Commercial Individual membership implies 10% fall from a year ago, while our model estimate indicates a 12.2% decline. Also, declining memberships in Medicaid (-5.8%) are likely to have kept second-quarter performance in check. However, the consensus estimate for Commercial Fee-based memberships indicates 1.9% year-over-year growth.

Meanwhile, the Zacks Consensus Estimate for Carelon brand’s operating income for the second quarter indicates a 3.8% year-over-year decrease. The consensus estimate for the Health Benefits segment’s operating income for the second quarter indicates a 34.7% year-over-year plunge, making an earnings beat uncertain.

The Zacks Consensus Estimate for the benefit expense ratio is pegged at 89.4, higher than the year-ago level of 88.9, which could further weigh on profitability during the quarter.

Stocks That Warrant a LookWhile an earnings beat looks uncertain for Elevance, here are some companies from the broader Medical space that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this time around:

ProMIS Neurosciences, Inc. (PMN - Free Report) has an Earnings ESP of +13.30% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.

The Zacks Consensus Estimate for ProMIS’ bottom line for the to-be-reported quarter of a loss of $1.45 indicates 80% year-over-year improvement. It has witnessed one upward revision against no downward movement over the past 60 days.

Alcon Inc. (ALC - Free Report) has an Earnings ESP of +1.83% and a Zacks Rank of 2.

The Zacks Consensus Estimate for Alcon’s bottom line for the to-be-reported quarter indicates 1.3% increase from a year ago. The company’s earnings beat estimates in three of the trailing four quarters and missed once, with an average surprise of 3.7%. The consensus estimate for ALC’s revenues is pegged at $2.77 billion, signaling 7.3% increase.

Cardinal Health, Inc. (CAH - Free Report) has an Earnings ESP of +1.24% and a Zacks Rank of 2.

The Zacks Consensus Estimate for Cardinal Health’s bottom line for the to-be-reported quarter predicts 16.4% year-over-year growth. Its earnings beat estimates in each of the past four quarters, with an average surprise of 10.3%. CAH’s revenues for the to-be-reported quarter are pegged at $65.61 billion, a 9.1% increase from the year-ago period.

This week’s Elevance Health and UnitedHealth Group quarterly earnings are much anticipated for signs these companies’ health insurance businesses and their rivals are keeping a handle on rising costs. In this photo, UnitedHealthcare health insurance company signage is displayed on an office building in Phoenix, Arizona on July 19, 2023. (Photo by Patrick T. Fallon / AFP) (Photo by PATRICK T. FALLON/AFP via Getty Images)

AFP via Getty Images

This week’s Elevance Health and UnitedHealth Group quarterly earnings are much anticipated for signs these companies’ health insurance businesses and that of their rivals are keeping a handle on rising costs.

Elevance, which owns Blue Cross and Blue Shield plans in 14 states, and UnitedHealth, which owns the nation’s largest health insurer in UnitedHealthcare, will be the first health insurers to report second quarter earnings as the industry works to exit a period of higher-than-expected medical costs.

These insurers’ earnings reports report will offer clues as to whether the sector may finally be turning the corner after most health plans reported medical loss ratios north of 90% until the trend was interrupted with lower costs in the first quarter of this year. Such a ratio, which is the percentage of premium revenue that goes toward medical costs, was above 90% for much of 2025 for many insurers.

In the first quarter of this year, however, Elevance, which is the nation’s second-largest health insurer behind UnitedHealthcare, reported a benefit expense ratio eclipsing 86%. Elevance manages Medicaid coverage for poor Americans via contracts with multiple states, sells Medicare Advantage for older adults and markets commercial health insurance including individual coverage under the Affordable Care Act, also known as Obamacare. The company also has a growing Carelon healthcare services business.

“The benefit expense ratio was 86.8 percent, an increase of 40 basis points, reflecting expected elevated medical cost trend in our Medicaid business, partially offset by improved performance in Medicare,” Elevance Health said in its first quarter earnings statement.

MORE FOR YOU

Analysts who follow the industry say they expect second quarter earnings reports to show that companies have maintained their handle on medical cost trends, particularly in their Medicare Advantage plans. Medicare Advantage plans contract with the federal government to provide coverage available in traditional Medicare plus extra benefits and services to seniors, such as disease management and nurse help hotlines with some also offering vision, dental care and wellness programs.

UnitedHealth said in its first quarter report that its “medical cost ratio was 83.9% for the first quarter 2026, down 90 basis points from the first quarter 2025.”

Elevance reports Wednesday, July 15 and UnitedHealth reports Thursday, July 16.

Elevance Health has outperformed the benchmark, rising 28% versus 11%, and I see further upside potential. ELV demonstrates steady top- and bottom-line growth, supporting a premium multiple and reinforcing management confidence. The insurance market's steady growth is a structural tailwind; if ELV maintains market share, it stands to benefit.

In its upcoming report, Elevance Health (ELV - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $6.18 per share, reflecting a decline of 30.1% compared to the same period last year. Revenues are forecasted to be $48.45 billion, representing a year-over-year decrease of 2%.

The current level reflects a downward revision of 0.1% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.

Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.

While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.

That said, let's delve into the average estimates of some Elevance Health metrics that Wall Street analysts commonly model and monitor.

Analysts predict that the 'Revenues- Net investment income' will reach $446.85 million. The estimate points to a change of -8.1% from the year-ago quarter.

Analysts' assessment points toward 'Revenues- Service fees' reaching $2.24 billion. The estimate indicates a change of +6% from the prior-year quarter.

The average prediction of analysts places 'Revenues- Premiums' at $39.90 billion. The estimate indicates a year-over-year change of -3.3%.

The consensus estimate for 'Revenues- Product revenue' stands at $6.32 billion. The estimate suggests a change of +4.7% year over year.

The combined assessment of analysts suggests that 'Total Medical Membership' will likely reach 44.82 million. Compared to the present estimate, the company reported 45.62 million in the same quarter last year.

Based on the collective assessment of analysts, 'Medical Membership - Medicare - Medicare Advantage' should arrive at 1.87 million. Compared to the current estimate, the company reported 2.26 million in the same quarter of the previous year.

According to the collective judgment of analysts, 'Medical Membership - Medicaid' should come in at 8.23 million. Compared to the present estimate, the company reported 8.73 million in the same quarter last year.

Analysts forecast 'Medical Membership - Federal Employees Health Benefits' to reach 1.56 million. Compared to the current estimate, the company reported 1.64 million in the same quarter of the previous year.

Analysts expect 'Medical Membership - Total Medicare' to come in at 2.75 million. Compared to the current estimate, the company reported 3.13 million in the same quarter of the previous year.

The consensus among analysts is that 'Medical Membership - Commercial Risk-Based - Individual' will reach 1.21 million. The estimate compares to the year-ago value of 1.35 million.

It is projected by analysts that the 'Benefit Expense Ratio' will reach 89.4%. The estimate compares to the year-ago value of 88.9%.

The collective assessment of analysts points to an estimated 'Medical Membership - Commercial Fee-Based' of 27.68 million. Compared to the current estimate, the company reported 27.15 million in the same quarter of the previous year.

View all Key Company Metrics for Elevance Health here>>>

Elevance Health shares have witnessed a change of +5.3% in the past month, in contrast to the Zacks S&P 500 composite's +2.2% move. With a Zacks Rank #2 (Buy), ELV is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health (NYSE: ELV) will release second quarter 2026 financial results on July 15, 2026, at 6:00 a.m. Eastern Daylight Time (“EDT”). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 - Access Code - 3972058 (Domestic) 312-470-0178 - Access Code - 3972058 (International) 800-39.

Key Takeaways Elevance Health's Carelon contributes 36.3% of operating revenues, expanding beyond health insurance.ELV said CareBridge cut readmissions 20% and saved over 10% in post-acute care costs.Carelon's Q1 2026 operating gain fell 3.8%, but investments support long-term growth prospects. Carelon is emerging as a key pillar of Elevance Health, Inc.'s (ELV - Free Report) long-term growth strategy as the company expands beyond traditional health insurance. Through its integrated care delivery, pharmacy and care management businesses, Carelon is helping improve clinical outcomes while creating new revenue opportunities. The segment now contributes around 36.3% of Elevance Health's total operating revenues, underscoring its growing role in the company's diversified business model.

The business is also becoming a meaningful driver of operational efficiency. Carelon combines AI, predictive analytics and coordinated care programs to identify high-risk patients earlier and intervene before medical conditions worsen. Its integrated CareBridge and care-at-home platform has reduced hospital readmissions by 20% while generating over 10% savings in post-acute care costs. These capabilities also support higher medication adherence, fewer emergency room visits and improved care coordination, reinforcing Carelon's competitive position.

However, Carelon's first-quarter 2026 operating gain declined 3.8% year over year due to lower affiliated health plan membership and continued investments in expanding risk-based programs. Even so, these investments are laying the foundation for future growth. Specialty pharmacy, CareBridge and integrated medical-pharmacy solutions continue to gain traction, supporting Carelon's long-term growth prospects as employers seek more cost-effective healthcare solutions.

Carelon's growing role complements ELV's broader financial momentum. Operating revenues rose 1.5% year over year in the first quarter of 2026, and the company raised its 2026 adjusted EPS guidance to at least $26.75. As Carelon scales its clinical and pharmacy capabilities, it is well positioned to become a key contributor to Elevance Health's earnings growth and competitive advantage.

How Are Competitors Faring?

Some of ELV’s major competitors in the value-based care space are UnitedHealth Group Incorporated (UNH - Free Report) and Humana Inc. (HUM - Free Report) .

UnitedHealth, through its Optum segment, is scaling AI-driven care management, pharmacy and provider solutions to improve care coordination and operational efficiency. Its integrated care model supports value-based reimbursement while diversifying revenues beyond its insurance business. UnitedHealth’s total revenues rose 2% year over year in the first quarter of 2026.

Humana is strengthening its integrated care strategy through CenterWell, which combines primary care, home health and pharmacy services. The company continues expanding value-based care and home-based services, aiming to improve patient outcomes while controlling medical costs. Humana’s total revenues rose 23.5% year over year in the first quarter of 2026.

Elevance Health’s Price Performance, Valuation & EstimatesShares of ELV have risen 12.1% in the year-to-date period against the industry’s fall of 2.9%.

Image Source: Zacks Investment Research

From a valuation standpoint, Elevance Health trades at a forward price-to-earnings ratio of 13.85, below the industry average of 15.70. ELV carries a Value Score of A.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for Elevance Health’s 2026 earnings is pegged at $26.92 per share, implying an 11.1% drop from the year-ago period.

Image Source: Zacks Investment Research

ELV stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

INDIANAPOLIS--(BUSINESS WIRE)--Thomas Carr Howe Middle School today celebrated the unveiling of a newly transformed fitness and strength training space made possible through a partnership with Elevance Health and the Impact Fitness Foundation (IFF).

“Strong communities are built when young people have the support and opportunity they need to thrive,” Gail K. Boudreaux, President and Chief Executive Officer of Elevance Health

Share The project marks the fifth consecutive year that Elevance Health and IFF have invested in Indianapolis schools through community fitness initiatives connected to the Elevance Health Women’s Fort Myers Tipoff, a premier collegiate basketball tournament that celebrates the impact of women in sports.

More than 40 Elevance Health volunteers worked alongside representatives from the Impact Fitness Foundation to renovate the school’s fitness and athletic training areas, creating a modern, welcoming environment designed specifically for middle school students. The project included installation of new flooring, fitness equipment, storage systems, and organizational improvements that will support year-round student wellness and athletic development.

But school leaders say the true impact will be measured not by the equipment installed, but by the opportunities it creates.

The renovated facility will serve as the home for expanded strength and conditioning programming, open gym opportunities, and student-athlete development activities throughout the summer and school year. “This space opens the door to opportunities our students simply didn’t have before,” said William Clay, Athletic Director at Thomas Carr Howe Middle School. “We're excited to provide structured strength and conditioning opportunities, create new experiences for our female student-athletes, and help students build habits that support their health, confidence, and success both on and off the field of play.”

The initiative reflects Elevance Health’s commitment to improving whole health by investing in the places where young people live, learn, and play.

“Strong communities are built when young people have the support and opportunity they need to thrive,” said Gail K. Boudreaux, President and Chief Executive Officer of Elevance Health. “Over the past five years, our partnership with the Impact Fitness Foundation and the Elevance Health Women’s Fort Myers Tipoff has helped schools create spaces that promote movement, well-being, and connection. We are proud of the impact we’ve made together and look forward to continuing to empower the next generation to lead healthier, brighter lives.”

The connection to the Women’s Fort Myers Tipoff is especially meaningful this year as Elevance Health and the Impact Fitness Foundation celebrate their fifth year of a partnership dedicated to helping young people thrive through sports and fitness, while advancing the tournament’s commitment to supporting and empowering young women both on and off the court.

“Research consistently shows that girls are more likely to leave sports and organized fitness programs during adolescence,” said Chris Welsh, Founder and President of the Impact Fitness Foundation. “Creating welcoming spaces and intentional programming can make a tremendous difference. We’re excited to see Howe use this facility not only to support athletics, but also to help young people—especially young women—discover confidence, leadership, and a lifelong connection to health and wellness.”

Following the ribbon-cutting ceremony, coaches, staff members, and student-athletes participated in an instructional clinic led by Impact Fitness Foundation trainers to learn proper equipment use, strength-training fundamentals, and best practices for maintaining the new facility.

About Elevance Health
Elevance Health is a lifetime, trusted health partner whose purpose is to improve the health of humanity. The company supports consumers, families, and communities across the entire healthcare journey – connecting them to the care, support, and resources they need to lead better lives. Elevance Health’s companies serve approximately 105 million consumers through a diverse portfolio of industry-leading medical, pharmacy, behavioral, clinical, home health, and complex care solutions. For more information, please visit www.elevancehealth.com or follow us @ElevanceHealth on X and Elevance Health on LinkedIn.

About Impact Fitness Foundation
The Impact Fitness Foundation is a national nonprofit organization dedicated to creating fitness and movement opportunities in underserved communities. Through facility transformations, programming, education, and training, IFF helps individuals of all ages build healthier futures through movement and wellness.

More News From Elevance Health, Inc.